Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 1.23% and Operating profit at -10.03% over the last 5 years
2
The company has declared Positive results for the last 3 consecutive quarters
3
With ROE of 11.11%, it has a very attractive valuation with a 2.63 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 12,105 Million (Large Cap)
24.00
NA
2.02%
-0.06
11.11%
2.67
Revenue and Profits:
Net Sales:
876 Million
(Quarterly Results - Sep 2025)
Net Profit:
114 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.26%
0%
-6.26%
6 Months
-6.77%
0%
-6.77%
1 Year
32.01%
0%
32.01%
2 Years
56.59%
0%
56.59%
3 Years
-7.85%
0%
-7.85%
4 Years
-31.12%
0%
-31.12%
5 Years
-40.3%
0%
-40.3%
Xiamen Kingdomway Group Co. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.23%
EBIT Growth (5y)
-10.03%
EBIT to Interest (avg)
19.01
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.03
Sales to Capital Employed (avg)
0.60
Tax Ratio
21.11%
Dividend Payout Ratio
71.34%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
15.55%
ROE (avg)
13.09%
Valuation key factors
Factor
Value
P/E Ratio
24
Industry P/E
Price to Book Value
2.63
EV to EBIT
20.37
EV to EBITDA
14.63
EV to Capital Employed
2.64
EV to Sales
3.31
PEG Ratio
0.21
Dividend Yield
2.14%
ROCE (Latest)
12.95%
ROE (Latest)
11.11%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
875.80
901.20
-2.82%
Operating Profit (PBDIT) excl Other Income
152.90
186.10
-17.84%
Interest
15.00
11.10
35.14%
Exceptional Items
1.20
-7.00
117.14%
Consolidate Net Profit
114.30
116.40
-1.80%
Operating Profit Margin (Excl OI)
174.60%
146.00%
2.86%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is -2.82% vs 8.95% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is -1.80% vs -5.29% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
3,236.20
3,096.20
4.52%
Operating Profit (PBDIT) excl Other Income
661.90
540.90
22.37%
Interest
31.50
42.20
-25.36%
Exceptional Items
-12.90
-18.40
29.89%
Consolidate Net Profit
367.00
276.20
32.87%
Operating Profit Margin (Excl OI)
138.80%
104.90%
3.39%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 4.52% vs 3.27% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 32.87% vs 12.69% in Dec 2023
About Xiamen Kingdomway Group Co. 
Xiamen Kingdomway Group Co.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






